Orphan drug: Development trends and strategies
نویسندگان
چکیده
منابع مشابه
Orphan drug: Development trends and strategies
The growth of pharma industries has slowed in recent years because of various reasons such as patent expiries, generic competition, drying pipelines, and increasingly stringent regulatory guidelines. Many blockbuster drugs will loose their exclusivity in next 5 years. Therefore, the current economic situation plus the huge generic competition shifted the focus of pharmaceutical companies from t...
متن کاملEthical issues in funding orphan drug research and development.
This essay outlines the moral dilemma of funding orphan drug research and development. To date, ethical aspects of priority setting for research funding have not been an issue of discussion in the bioethics debate. Conflicting moral obligations of beneficence and distributive justice appear to demand very different levels of funding for orphan drug research. The two types of orphan disease, rar...
متن کاملChallenges in orphan drug development and regulatory policy in China
While regulatory policy is well defined for orphan drug development in the United States and Europe, rare disease policy in China is still evolving. Many Chinese patients currently pay out of pocket for international treatments that are not yet approved in China. The lack of a clear definition and therefore regulatory approval process for rare diseases has, until now, de-incentivized pharmaceut...
متن کاملCrafting a robust business model for orphan drug development.
As research into drugs targeting rare or ‘‘orphan’’ diseases has stepped up in recent years, so too has the need for a robust business model capable of bringing promising orphan drugs into the marketplace. The earliest step took place in 1983, when President Ronald Reagan signed into law the Orphan Drug Act. More than a quarter-century later, the orphan disease community is looking again to Was...
متن کاملMethadone: An Orphan Drug?
73 Dear Editor: A pharmaceutical product is called “orphan drug” when, although promising or clearly valid from a scientific and therapeutic point of view, it is not profit-bearing and, therefore, not interesting for the pharmaceutical industry. The consequences are the lack of extensive research on its effects, and mainly, the lack of appropriate information to physicians, nurses, and administ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Pharmacy and Bioallied Sciences
سال: 2010
ISSN: 0975-7406
DOI: 10.4103/0975-7406.72128